TB-500

What it is

TB-500 is a synthetic version of a specific segment of Thymosin Beta-4 (Tβ4), a protein naturally produced by the thymus gland. While Tβ4 is a large molecule found in almost all human and animal cells, TB-500 focuses on the active "healing" part of that sequence. It was originally studied in the veterinary world to help racehorses recover from injuries before transitioning into human research.

The molecule is specifically designed to be lightweight, allowing it to travel through the body easily to reach sites of injury. We view it as a signaling molecule that tells the body to move "repair" cells to wherever they are needed most.

What it does

TB-500 works by binding to actin, a major protein involved in cell structure and movement. By regulating actin levels, the peptide helps cells migrate to injured areas to begin the reconstruction process. This mechanism is vital for skin, muscle, and ligament repair.

Users generally explore TB-500 for its ability to reduce inflammation and promote flexibility in joint tissue. Unlike BPC-157, which often acts locally near the injection site, TB-500 is considered systemic, meaning it can circulate and address multiple issues at once. Research has also investigated its potential to protect the heart and brain after traumatic events by reducing scar tissue formation.

What the evidence says

The evidence for TB-500 is robust in preclinical and animal settings. Studies on horses and rodents have shown it can significantly accelerate the healing of corneal ulcers and muscle tears. It is particularly well-known for its "anti-fibrotic" effects, meaning it helps prevent the formation of stiff scar tissue that can limit range of motion.

Human data is more sparse. While Thymosin Beta-4 (the parent molecule) has undergone some Phase 2 clinical trials for wound healing and dry eye syndrome, the specific synthetic fragment TB-500 hasn't seen the same level of rigorous human testing. Most of what we know about its efficacy in humans comes from observational data and the experiences of high-level athletes.

What it costs

TB-500 is typically sold in 2mg, 5mg, or 10mg vials. In the US, a 5mg vial usually costs between $60 and $90. Because this peptide is often used in "loading" cycles, a typical monthly outlay for research purposes can range from $150 to $400.

Side effects and risks

Reported side effects are generally mild and include temporary tiredness, head rushes immediately after use, or redness at the site of administration. However, like other growth-promoting peptides, there is a theoretical concern that it could accelerate the growth of existing tumors by increasing blood supply to those areas.

In April 2026, the FDA removed TB-500 from the Category 2 bulk substances list, scheduling it for PCAC review (July 23, 2026) for possible 503A inclusion. Compounding remains restricted in the meantime. TB-500 is also strictly banned by WADA and most professional sporting organizations.

Where users source it

Because it is not FDA-approved for human use, TB-500 is sourced through research chemical websites. These labs operate in a gray market, so quality control is paramount. We advise looking for providers who offer HPLC (High-Performance Liquid Chromatography) testing results to verify that the peptide sequence is accurate and the purity is high.

Sources

• Philp D, et al. (2004). "Thymosin beta4 promotes angiogenesis." Nature Medicine. PMID 15302914
• Goldstein AL, et al. (2012). "Thymosin beta4: a multi-functional regenerative peptide." PMID 22197637
• Sosne G, et al. (2010). "Thymosin beta 4: a novel corneal wound healing agent." Experimental Eye Research. PMID 20171206
• FDA. (2023). "Safety Risks of Certain Peptides."